Search Results
Your search for The ASCO Post,The ASCO Post matches 17625 pages
Showing 15851 - 15900APOS Announces 2015 Award Winners at the World Congress of Psycho-Oncology
The American Psychosocial Oncology Society (APOS) honored five award winners at the 2015 World Congress of Psycho-Oncology, held from July 28–August 1 in Washington, DC. Holland Distinguished Leadership Award: Matthew J. Loscalzo, LCSW Professor Loscalzo is the Liliane Elkins Professor in...
Penn’s Basser Center for BRCA Names David Livingston, MD, Winner of 2015 Annual Basser Global Prize
The Basser Center for BRCA at Penn’s Abramson Cancer Center has announced the recipient of its third annual Basser Global Prize: molecular cancer expert David Livingston, MD, Emil Frei Professor of Genetics and Medicine at Harvard Medical School and Deputy Director of the Dana-Farber/Harvard...
Improved Understanding of Glioma Tumor Biology
The management of patients with lower-grade gliomas is evolving. As evidenced by two recent publications in The New England Journal of Medicine,1,2 reviewed in this issue of The ASCO Post, there has been a substantial increase in our knowledge of the molecular characteristics of these neoplasms....
The Conundrum of Estrogen-Receptor Signaling in HER2-Positive Breast Cancer
BOLERO-1—reviewed in this issue of The ASCO Post—is the next installment in a series of randomized trials evaluating the addition of everolimus (Afinitor) to standard therapy in metastatic breast cancer.1 The initial evaluation of everolimus in the HER2-positive metastatic setting looked extremely...
Calculating the Value of Cancer Drugs
For nearly a decade, Peter B. Bach, MD, MAPP, Director of the Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center in New York, has been a leading voice in sounding the alarm over the escalating cost of cancer drugs and in seeking a solution to the problem. In 2012, Dr....
Children’s Hospital of Philadelphia Appoints Madeline Bell, MS, as CEO
The Children’s Hospital of Philadelphia (CHOP) announced that Madeline Bell, MS, formerly President and Chief Operating Officer, has been appointed President and Chief Executive Officer and will succeed Steven M. Altschuler, MD, as CEO. The transition of leadership was completed on July 1, 2015....
Learning to Refine the Use of Regorafenib to Best Advantage in Advanced Colorectal Cancer
In patients with advanced colorectal cancer who have been heavily treated with a sequence of chemotherapy regimens and/or targeted therapies, the goals of treatment on or off a clinical trial are readily definable. These patients and their managing teams are striving to extend the length of lives,...
FDA Approves Sonidegib for Locally Advanced Basal Cell Carcinoma
The U.S. Food and Drug Administration (FDA) approved sonidegib (Odomzo) for the treatment of patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy or those who are not candidates for surgery or radiation therapy. The approval was based on...
Dactinomycin Formulation Gets Orphan Drug Designation
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to NanoSmart Pharmaceuticals’ novel formulation of dactinomycin for the treatment of Ewing sarcoma, a rare type of childhood bone cancer. The designation was granted on the basis of a plausible hypothesis that the novel ...
FDA Grants Breakthrough Therapy Designation to Lenvatinib for Metastatic Renal Cell Carcinoma
The U.S. Food and Drug Administration (FDA) granted lenvatinib (Lenvima) Breakthrough Therapy designation for investigational use in patients with advanced or metastatic renal cell carcinoma who were previously treated with a vascular endothelial growth factor (VEGF)-targeted therapy. Lenvatinib...
FDA Approves Carfilzomib Combination for Patients With Relapsed Multiple Myeloma
The U.S. Food and Drug Administration (FDA) approved carfilzomib (Kyprolis) in combination with lenalidomide (Revlimid) and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy. In the United States, there are nearly...
Studies Explore New Avenues to Pursue in Metastatic Triple-Negative Breast Cancer
Two agents targeting novel pathways show promise in metastatic triple-negative breast cancer, according to separate studies presented at the 2015 ASCO Annual Meeting and reviewed at the Best of ASCO® meeting by Steven J. Isakoff, MD, PhD, of Massachusetts General Hospital, Boston. The first study...
James Welsh, MD, FACRO, Elected President of the American College of Radiation Oncology
Loyola University Medical Center radiation oncologist James Welsh, MD, FACRO, was recently elected president of the American College of Radiation Oncology (ACRO). Dr. Welsh, installed as president during ACRO’s Annual Meeting in Washington, DC, will serve a 2-year term as President. In 2017, Dr....
Joxel Garcia, MD, to Direct MD Anderson Moon Shots Program Prevention Efforts
The University of Texas MD Anderson Cancer Center has appointed former United States Public Health Service four-star Admiral Joxel Garcia, MD, as the inaugural Executive Director of the Cancer Prevention and Control Platform, part of MD Anderson’s Moon Shots Program. He joined MD Anderson on August ...
Expect Questions or Ask About Postmastectomy Pain
Since postmastectomy pain occurs in an estimated 20% to 40% of patients undergoing the procedure, physicians who treat these women can expect questions about the pain and how to deal with it. However, some patients may be reluctant to ask about it. “Sometimes, women don’t want to complain to their ...
Increased Interest in Simple Injection to Treat Women With Postmastectomy Pain
After presenting results of a study showing that injecting a standard analgesic combination into trigger points of pain along the inframammary fold relieved postmastectomy pain, Laura J. Esserman, MD, MBA, Director of the Carol Franc Buck Breast Care Center and Co-Leader of the Breast Oncology...
Mayo Clinic Receives $11 Million Grant from NCI to Study NHL Survivorship
Mayo Clinic has received a 5-year, $11 million grant from the National Cancer Institute (NCI) to study survivorship in patients with non-Hodgkin lymphoma (NHL). The Lymphoma Epidemiology of Outcomes Cohort Study will enroll 12,000 patients with NHL. The study will follow these patients for...
Unneccessary Complexity in Scientific Terminology?
In the highlighted quote in the article titled “Ado-Trastuzumab Emtansine Fails to Replace Standard of Care in First-Line Metastatic Breast Cancer,” which appeared in on page 3 of the July 10 issue of The ASCO Post, a most remarkable sentence was constructed: T-DM1 and T-DM1 plus pertuzumab...
2015 Oncology Meetings
SEPTEMBER 2015 Breast Cancer SymposiumSeptember 25-27 • San Francisco, California For more information: breastcasym.org The European Cancer CongressSeptember 25-29 • Vienna, Austria For more information: www.esmo.org/Conferences/European-Cancer-Congress-2015 17th Annual International Meeting of...
ASCO and UICC Collaborate to Extend Reach of the Journal of Global Oncology
ASCO and the Union for International Cancer Control (UICC) announced their partnership to expand the reach of the Journal of Global Oncology (JGO), a new open-access journal that will focus on cancer care, research, and care delivery issues unique to countries and settings with limited health-care...
From Small-Town Mexico to Big Pharma, a Look at Opiates for Good and Bad
Bookmark Title: Dreamland: The True Tale of America’s Opiate Epidemic Author: Sam Quinones Publisher: Bloomsbury Press Publication date: April 21, 2015 Price: $28.00; hardcover, 384 pages Despite growing awareness within the oncology community and the emergence of the palliative care...
Chris Marshall, FRS, FMedSci, Dies at 66 of Colorectal Cancer
Chris Marshall, FRS, FMedSci, a rigorous scientist with a lasting legacy of game-changing discoveries in cancer research and generous support for his younger colleagues, has died at 66. The cause of death was colorectal cancer. Professor Marshall was the Head of the Division for Cancer Biology at...
Breast Surgeon Carolyn Mary Kaelin, MD, MPH, FACS, Dies at 54
Carolyn Mary Kaelin, MD, MPH, FACS, died on July 28 at the age of 54. A gifted and compassionate breast cancer surgeon, Dr. Kaelin was a surgical oncologist in the Women’s Cancers Program at Dana-Farber Cancer Center and Director of the Breast Clinic at Brigham and Women’s Hospital. Dr. Kaelin...
Coriolus versicolor
The use of dietary supplements by patients with cancer has increased significantly over the past 20 years despite insufficient evidence of safety and effectiveness. Finding reliable sources of information about dietary supplements can be daunting. Patients typically rely on family, friends, and the ...
Diane Simeone, MD, Named Upcoming Chair of PanCAN Scientific Board
Diane Simeone, MD, Director of the Pancreatic Cancer Center at the University of Michigan, was recently named the Upcoming Chair of the National Scientific and Medical Advisory Board for the Pancreatic Cancer Action Network (PanCAN). Her 2-year term as Chair runs from 2017 to 2019. Dr. Simeone will ...
Thomas J. Lynch Jr, MD, Leaves Yale Cancer Center
Thomas J. Lynch Jr, MD, Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital at Yale-New Haven, left Yale in August to become Chairman and Chief Executive Officer of the Massachusetts General Physicians Organization. Dr. Lynch joined Yale Cancer Center as Director in 2009 ...
A Cancer Handbook for Inquisitive Laypersons and Health-Care Professionals
Bookmark Title: The Cancer Solution: Taking Charge of Your Life With CancerAuthor: Jack C. Westman, MD, MSPublisher: Archway PublishingPublication date: January 15, 2015Price: $20.00; paperback, 310 pages I was at a meeting in San Francisco in 1978 and received a call from my wife, Nancy:...
Hypertrophic Tumor of the Forehead, Philadelphia, Circa 1870
Through the Lens of Oncology History: A Century of Progress The text and photographs on this page are excerpted from a four-volume series of books titled Oncology Tumors & Treatment: A Photographic History, by Stanley B. Burns, MD, FACS. The photos below are from the volume titled “The...
Andrew S. Chi, MD, PhD, Named Head of Neuro-Oncology at NYU’s Laura and Isaac Perlmutter Cancer Center
New York University (NYU) Langone Medical Center announced the appointment of physician-scientist and brain tumor specialist Andrew S. Chi, MD, PhD, as Chief of Neuro-Oncology for its Laura and Isaac Perlmutter Cancer Center and Co-Director of the NYU Langone Brain Tumor Center. In his new role,...
Iuliana Shapira, MD, Named Chief of Hematology and Oncology at SUNY Downstate
Iuliana Shapira, MD, has joined SUNY Downstate Medical Center as Chief of the Division of Hematology and Oncology. In this position, Dr. Shapira will provide leadership in the clinical, academic, and administrative aspects of the program, as well as broaden the relationship with SUNY Downstate’s...
Jeffrey Rathmell, PhD, to Lead New Center for Immunobiology at Vanderbilt
Jeffrey Rathmell, PhD, has been recruited to Vanderbilt University Medical Center (VUMC) to lead a new Center for Immunobiology, a structure supported by the Department of Pathology, Microbiology, and Immunology, the Department of Medicine, and Vanderbilt-Ingram Cancer Center (VICC). He took on his ...
W. Kimryn Rathmell, MD, PhD, Will Direct Division of Hematology and Oncology at Vanderbilt
W. Kimryn Rathmell, MD, PhD, Alexander Professor for Translational Science and Associate Director for Training and Education at the University of North Carolina’s Lineberger Comprehensive Cancer Center, has been named Director of Vanderbilt’s Division of Hematology and Oncology. She began her new...
The Flipped Classroom: Swapping the Traditional Lecture Hall for an Online Version
Despite enormous advances in modern medicine and the explosion of biomedical information over the past century, the way medical education is taught in the United States is stuck in a format that does not optimize learning, according to Charles Prober, MD, Senior Associate Dean for Medical Education ...
Access to Cancer Medicines Not Uniform Across Europe
Access to cancer medicines—including some old standbys—is inconsistent across Europe, depriving many patients of treatments that are the standard of care elsewhere,1 according to Alexandru E. Eniu, MD, PhD, Chair of the European Society for Medical Oncology (ESMO) Emerging Countries Committee and...
Massimo Cristofanilli, MD, Named Associate Director for Precision Medicine and Translational Research at Lurie Cancer Center
Breast cancer expert Massimo Cristofanilli, MD, has been appointed Associate Director for Precision Medicine and Translational Research at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Director of Northwestern Onco-SET (Sequence, Evaluate, Treat). Dr. Cristofanilli ...
Seventeen ASTRO Members Awarded Fellows Designation
The American Society for Radiation Oncology (ASTRO) has selected 17 distinguished members to receive the ASTRO Fellows designation. The 2015 class of Fellows will receive the recognition at the Awards Ceremony at ASTRO’s 57th Annual Meeting on Tuesday, October 20 in San Antonio, Texas. ASTRO...
COMBI-d Trial and the Need to Guide Progress in Melanoma Treatment
As reviewed in this issue of The ASCO Post, Long et al1 have reported the final overall survival analysis of the COMBI-d phase III trial comparing combination therapy with the BRAF inhibitor dabrafenib (Tafinlar) and the MEK inhibitor trametinib (Mekinist) to monotherapy with dabrafenib alone,...
St. Jude Names Keith Perry, MBA, as Chief Information Officer
St. Jude Children’s Research Hospital has named Keith Perry, MBA, as Chief Information Officer (CIO) to provide strategic counsel and leadership for the hospital’s information technology initiatives. “Our internal information technology systems and operations play a critical role in the success...
Getting There From Here: What You Need to Know About Traveling to Cuba
In January 2015, the U.S. Department of the Treasury and the U.S. Department of Commerce announced changes related to the easing of sanctions on Cuba, which loosened some restrictions on travel for Americans, although some rules still apply. There are 12 legal categories of travel to Cuba,...
Resilient New Orleans: 10 Years After Katrina
It’s been 10 years since floodwaters washed away lives in New Orleans—for most, figuratively or temporarily, but for more than 1,800, literally. We who call this place home all lost something—homes, possessions, jobs, pets, loved ones, our sanity. Mold and muck marked our days for a long time, but...
State-of-the-Art Management of Germ Cell Tumors Produces High Cure Rates
Pasquale W. Benedetto, MD, the Leonard M. Miller Professor of Medicine at the University of Miami/Sylvester Comprehensive Cancer Center, recently spoke at the 2015 New Orleans Summer Cancer Meeting about his approach to diagnosing and treating germ cell tumors in men.1 The ASCO Post was there to...
NCI and Sage Bionetworks Present: Up for A Challenge?
The National Cancer Institute (NCI) Division of Cancer Control and Population Sciences is partnering with Sage Bionetworks for “Up for a Challenge (U4C): Stimulating Innovation in Breast Cancer Genetic Epidemiology.” This prize competition aims to explore the genomic basis of breast cancer in...
Coping With Aging and Cancer: Psychosocial Factors and Geriatric-Specific Interventions
You can’t control the wind, but you can adjust your sails,” said Mindy Greenstein, PhD, consulting psychologist and author, to begin her talk at the 2015 World Congress of Psycho-Oncology, held in July in Washington, DC. The sense of this proverb pervaded the entire session on cancer and aging....
Three New Officers Elected to ASTRO’s Board of Directors
The American Society for Radiation Oncology (ASTRO) has elected three new officers to the Board of Directors and three members to serve on the Nominating Committee. Terms for all positions begin on October 20, 2015 at ASTRO’s 57th Annual Meeting. The new officers to the Board of Directors are:...
IPOS Announces 2015 Award Winners at the World Congress of Psycho-Oncology
The International Psycho-Oncology Society (IPOS) announced four award winners at the 2015 World Congress of Psycho-Oncology, held July 28 to August 1 in Washington, DC. Arthur M. Sutherland Award: William H. Redd, PhD Dr. Redd is Professor of Oncological Sciences at the Mount Sinai Hospital. He is...
HPV16 DNA in Post-Treatment Oral Rinses Signals Poor Prognosis in Oropharyngeal Cancer
Detectable oral HPV16 DNA in oral rinses post treatment for oropharyngeal cancer appears to be a harbinger of poor prognosis and can predict recurrence. Oral HPV16 DNA rinses are a potential tool for long-term tumor surveillance, according to a study selected for the Best of ASCO® 2015.1 “The goal ...
Role of Surgery and Adjuvant Radiotherapy in the Treatment of Breast Cancer Explored
Two separate retrospective studies have further refined our understanding of the respective contributions of surgery and radiotherapy in the treatment of breast cancer. However, these studies are not definitive, and “gold standard” trials are needed to arrive at definitive recommendations. Both...
Indolent Lymphoma: A More Complex Malignancy Than Once Thought
With a growing number of options for follicular lymphoma, clinicians may wonder whether there is one best regimen. James O. Armitage, MD, FACP, FRCP, Professor of Medicine at the University of Nebraska, Omaha—and Editor-in-Chief of The ASCO Post—tackled this question and offered recommendations at...
Charting a New Course: From Clinical Investigator to University President
What first intrigued Fadlo R. Khuri, MD, FACP, about the prospect of becoming the 16th President of the American University of Beirut (AUB) in Lebanon was the chance to give back to an institution and a country that had given him so much. Born in Boston, Massachusetts, in 1963, Dr. Khuri was raised ...
Elotuzumab Ushers in a New Era in Myeloma Therapy
The long wait for monoclonal antibodies for the treatment of multiple myeloma is over. In the landmark ELOQUENT-2 study, reviewed in this issue of The ASCO Post, Lonial and colleagues convincingly demonstrate the effectiveness of elotuzumab, a monoclonal antibody directed against SLAMF7, in the...
